Biopharmaceutical firm Immunomedics of Morris Plains, NJ, announced last month that the District Court in the Hague upheld the company's European patent when it dismissed a legal action brought by Hoffman LaRoche. Basil, Switzerland-based LaRoche filed
Biopharmaceutical firm Immunomedics of Morris Plains, NJ, announced last month that the District Court in the Hague upheld the company's European patent when it dismissed a legal action brought by Hoffman LaRoche. Basil, Switzerland-based LaRoche filed the action in response to an infringement suit Immunomedics brought against it last fall. Immunomedics' European patent is valid in nine countries and covers CEA-specific antibodies as well as immunoassays which use CEA antibodies, according to the company's patent attorney, Bernhard Saxe of Foley & Lardner in Washington, DC.
In other Immunomedics news, the company last month reported that it has conferred a royalty-bearing, nonexclusive license to Dako A/S of Glostrup, Denmark, for its worldwide patents covering antibodies to CEA. Dako will sell the antibodies to pathology laboratories that stain tumor specimens for CEA.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
Emerging MRI Scoring System May Help Predict Recurrent and Metastatic Hepatocellular Carcinoma
February 12th 2025Preoperative use of the scoring system for gadoxetic acid-enhanced MRI demonstrated an average AUC of 85 percent and average specificity of 89 percent in external validation cohorts for pathologic features of hepatocellular carcinoma.
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC
February 11th 2025A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.